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Abstract
Background: One in four Swedish women suffers a hip fracture yielding high morbidity and mortality. We wanted
to revalidate a 4-item clinical risk score and evaluate a portable heel bone mineral density (BMD) technique
regarding hip and fragility fracture risk among elderly women.
Methods: In a population-based prospective cohort study we used clinical risk factors from a baseline
questionnaire and heel BMD to predict a two-year hip and fragility fracture outcome for women, in a fracture
preventive program. Calcaneal heel BMD was measured by portable dual X-ray laser absorptiometry (DXL) and
compared to hip BMD, measured with stationary dual X-ray absorptiometry (DXA) technique.
Results: Seven women suffered hip fracture and 14 women fragility fracture/s (at hip, radius, humerus and pelvis)
among 285 women; 60% having heel BMD ≤ -2.5 SD. The 4-item FRAMO (Fracture and Mortality) Index combined
the clinical risk factors age ≥80 years, weight <60 kg, prior fragility fracture, and impaired rise-up ability. Women
having 2-4 risk factors showed odds ratio (OR) for hip fracture of 5.9 and fragility fracture of 4.4. High risk group
hip fracture risk was 2.8% annually compared to 0.5% for the low risk majority (69%). Heel BMD showed hip
fracture OR of 3.1 and fragility fracture OR of 2.6 per SD decrease. For 30 DXA assessed participants mean hip BMD
at -2.5 SD level corresponded to a lower BMD at the heel. Five of seven hip fractures occurred within a small risk
group of 32 women, identified by high FRAMO Index + prior fragility fracture + heel T-score ≤-3.5 SD.
Conclusions: In a follow-up study we identified high risk groups for hip and fragility fracture with our plain 4-item
risk model. Increased fracture risk was also related to decreasing heel BMD in calcaneal bone, measured with a
mobile DXL technique. A combination of high FRAMO Index, prior fragility fracture, and very low BMD restricted
the high risk group to 11%, among whom most hip fractures occurred (71%). These practical screening methods
could eventually reduce hip fracture incidence by concentrating preventive resources to high fracture risk women.
Background
Hip fracture (HF) is a common and severe trauma, with
a 23% life time incidence in Swedish women[1-3]. More
than 90% of HF occur as a result of falls[4]. Prevention
of falls and/or fractures for these women can be
achieved by walking and mobility training, tobacco use
avoidance, home hazard reduction[5-11], pharmacologi-
cal treatment[12-21], and probably by use of hip protec-
tors[22,23].
HF risk group identification has been more fracture
predictive by combining several clinical risk factors than
by bone mineral density (BMD) assessment alone
[24-27]. However, additional BMD assessments further
improved fracture prediction[24,28,29].
Osteoporosis is diagnosed[1] when finding low BMD
compared to a reference population of young healthy
women. BMD values below T-score -1.0 SD is defined
as osteopenia and from T-score -2.5 SD and below as
osteoporosis. Osteoporosis combined with previous fra-
gility fracture is defined as established osteoporosis. A
typical fragility fracture usually occurs at distal radius,
proximal humerus, pubic and ischial pelvic bones, hip
or vertebrae after a low-energy trauma. BMD
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(DXA), rarely available in Swedish Primary Health care
(PMC), has been evaluated for both fracture prediction
and pharmacological treatment effects[30]. Optimal HF
risk prediction is achieved by the DXA, measured on
the hip (at “femoral neck” or “total hip”) with Relative
Risk (RR) at 2.6 per age-adjusted SD decrease[27,31,32].
HF prediction was slightly lower (RR = 2.0) when calca-
neal heel BMD was assessed with older X-ray techni-
ques, although the difference to assessment at hip was
non significant[31]. For vertebral fracture risk, spine
BMD assessment has better prediction or was in line
with hip assessment[27,31].
Osteoporosis prevalence varies for different popula-
tions or techniques, but it also depends on the number
of measured sites. DXA assessed hip osteoporosis
among Swedish women aged 70-84 was 28-47%[33]. Hip
osteoporosis prevalence among white US women aged
70-79 and ≥80 years was 24.5% and 47.5% respectively
[31,34], while choosing the lowest BMD of either hip,
spine and mid radius the prevalence increased to 38.5%
and 70.0%[34]. There is a need for improved fracture
prediction in Primary Health Care (PHC), to identify
individuals at high fracture risk and prevention needs,
and to protect women at minimal fracture risk from
unnecessary investigations and treatment[33].
A simple clinical 4-item risk score has shown 81%
sensitivity for two-year HF risk[35,36]. Additional BMD
assessment may narrow that risk group even more,
increasing the gain of bone strengthening therapy. A
portable and easily handled BMD measuring device,
Dual X-ray absorptiometry and Laser (DXL) technique,
could enable practical assessment in PHC[37]. Pre-
viously, DXL assessment has shown sensitivity/specificity
of 80% and 82% versus osteoporosis identification by
DXA assessment[37]. A retrospective DXL study showed
increased fracture history among women having low
BMD[37,38] but prospective fracture prediction from
DXL measure has not yet been demonstrated.
Our research question was “Does 4-item clinical risk
score or DXL assessed heel BMD, alone or in combina-
tion, predict HF or fragility fracture (FF)?” We therefore
decided to evaluate the two-year HF and FF risk in an
elderly female population, involved in a fracture preven-
tive programme.
Methods
Study population
This population-based PHC study included 285 of 390
women (73%) who answered a questionnaire and per-
formed BMD assessments in 2003, and were alive at fol-
low-up in 2004.
All 285 women for two years were part of an interven-
tion group in a controlled fracture preventive study
[35,39]. Clinical 4-item risk models were previously vali-
dated for fracture prediction during 2002-2003, based
on survey data from altogether 1248 women followed
during two years[35].
Questionnaire
In September 2003 while measuring BMD, 285 women
in the intervention area answered 15 questions on frac-
ture risk including age, weight, height, having fallen last
year, ability to rise five times from a chair without using
arms (recommended self-test), earlier fractures including
results of vertebral X-ray, family history of fractures,
smoking, cortisone medication, and living conditions
(see Table 1).
A 4-item risk model, Fracture and Mortality (FRAMO)
Index, evaluated previously in 2002-2003 among these
women[35] was now recalculated using data from the
current survey. Participants were classified at high frac-
ture risk, when fulfilling at least two of four binary risk
factors; age ≥80 years, weight <60 kg, previous fragility
fracture since age 50 years (located at distal radius,
proximal humerus, hip, or vertebrae), and impaired abil-
ity to rise.
Another earlier 4-item score, Risk Model II, with three
items being the same but “having fallen the last year”
was used instead of impaired ability to rise, was from
2003 used to direct the intervention types within the
study population[35,39]. The fracture risk for that
model was evaluated after previous study period 2002-
2003, showing risk ratios at lower levels than for the
FRAMO Index[36].
Heel BMD assessment with DXL
In September to October 2003 we performed bilateral
calcaneal heel BMD assessment in 285 of the 390 women
in the intervention population. The portable Dual X-ray
absorptiometry and Laser (DXL) Calscan device (article
number: PN 031000)[40] uses two X-ray energies in com-
bination with laser to determine the different absorptions
of bone mineral, lean soft tissues and adipose tissues[37],
with a precision CV% (coefficient of variability) in vivo of
1.24%[41]. DXL has no known physical side effects, was
easily managed by two assistant nurses and the first
author being trained by the equipment manufacturer
(Demetech). Software DXL Calscan Workstation version
1.2 was used to calculate heel T-scores from the refer-
ence data population Women-Europe-1001[38].
In our data analysis of bilateral heel assessment we
applied the lowest T-score of either side, because of
substantial side differences of T-score 0.5 SD or higher
among the 12% of women having substantially lower
right heel than left heel BMD. This regime lowered the
mean T-score with 0.18 SD as compared to a left side
assessment only (p < 0.001).
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Thirty consecutively chosen women accepted additional
DXA assessment. The DXA assessments were performed
at Ljungby hospital department of internal medicine
measuring both hips (total hip and femoral neck) and the
lumbar spine (between L2-L4). A Lunar DPX-Alpha
#8225 device was used, estimating T-scores from the
USA Femur Reference population and USA AP Spine
Reference population[42]. Additional 11 women were
DXA measured due to their heel T-score of ≤-3.5 SD.
We estimated BMD means and the correlation of
paired samples between the sites measured. In further
Table 1 Questionnaire data and heel BMD measured on 285 women at 2003.
285 women
Characteristics Replies of 285 Mean/N valid (%)*
Continuous risk factors
Heel BMD by DXL
†
T-score - Low side (SD)
† 285 -2.7 ± 1.0
T-score - Left side (SD) 284 -2.5 ± 1.0
T-score - Right side (SD) 283 -2.6 ± 1.0
Clinical risk factors
Age (years) 285 79 ± 5.3
Weight (kg) 284 68 ± 12
Height (cm) 276 160 ± 6.3
Risk groups with binary risk factors
Heel BMD by DXL
†
T-score ≥ -1.0 (SD) 285 13 (5)
-1.0 > T-score > -2.5 (SD) 285 101 (36)
-2.5 ≥ T-score > -3.5 (SD) 285 103 (36)
T-score ≤ -3.5 (SD) 285 68 (24)
T-score ≤ -2.5 (SD) + prior fragility fracture
‡ 283 70 (25)
T-score ≤ -3.5 (SD) + prior fragility fracture
‡ 283 35 (12)
Main clinical risk factors as combined
FRAMO Index
§ 285 88 (31)
Main clinical risk factors as single
Age ≥ 80 years 285 108 (38)
Weight < 60 kg 284 69 (24)
Prior fragility fracture since age 50
‡ 283 94 (33)
Impaired ability to rise five times from chair 278 52 (19)
Other possible risk factors
Any fall last 12 months 284 66 (23)
Cortisone medication more than 3 months 274 40 (15)
Living in residential care (vs community) 285 27 (9)
History of maternal hip fracture 274 33 (12)
Current smoking 284 12 (4)
* Percentage estimated on the valid participators and aritmetic mean value ± SD presented.
† Calcaneal BMD value measured bilateral by DXL-tecnique. Calculations usually made on the lowest value for either left or right heel.
‡ Prior fragility fracture is defined as fracture at hip, forearm, humerus, and vertebrae after 50 years of age.
§ FRAMO Index: High risk group has 2 of 4 risk factors of; Age ≥ 80 years, weight < 60 kg, prior fragility fracture and impaired ability to rise. Missing values
recoded to low fracture risk.
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site because HF is the most serious common fracture
type[2,3] and since BMD at hip is the most HF predic-
tive[31]. Also, in our sample we found heel to hip corre-
lations above r = 0.68.
Interventions
All 285 participants received a brochure with fall and
fracture preventive advice in 2002. The 22% (62/285)
of women, previously high risk classified (Risk Model
II at 2001)[35] got repeated house calls by a nurse in
2003. Nurses gave advice about life style, fall preven-
tion including safer home environment, and hip pro-
tectors. A physical home training programme was
introduced. Seven percent continued home training
until 2004 and 13% participated in physical group
training.
After the BMD assessment all participants received
information about their BMD and fracture risk. They
also got fracture preventive advice and 72% were con-
tacted by a physician individually. Following a major
intervention in 2004, 41% reported on-going treatment
with calcium and vitamin D and 13% taking a
bisphosphonate.
Fracture and mortality registration 2004 to 2005
We defined incident fragility fractures (FF) as fractures
occurring in the hip, distal radius, proximal humerus,
pubic bone, ischial bone and vertebrae during 2004-
2005. Vertebral fractures were classified as incident if
the radiograph report confirmed vertebral compression
in women who had local pain. We identified all incident
FF using diagnostic registers from the departments of
orthopaedics, and from radiological film reports. We
included diagnostic codes from ICD-10 [International
Classification of Diseases], S72.00-72.21, S52.50-60,
S42.20-21, S32.50, S32.80, S22.00 and S32.00.
Mortality data were collected from the National Swed-
ish Population Register.
Drop-outs
The original population of 435 women in the interven-
tion area decreased by 5.2% annually since 45 died
before the actual evaluation period 2004-2005, including
two women having done BMD assessment.
The 27% (105/390) non-participants in this study were
on average four years older, less able to rise up from
chair, and were more in residential care at 2001, com-
pared to the 285 participants.
After heel BMD assessment with DXL 46% (30/65) of
consecutively chosen women accepted and performed
an additional DXA investigation at hip and spine.
A m o n gw o m e nw i t hl o wh e e lB M D6 1 %( 1 1 / 1 8 )p e r -
formed the offered additional DXA assessment.
Ethics
The Regional Ethics Committee at Lund University
approved the study (LU 406-00). Also, the local radia-
tion protection committee at Växjö Central Hospital
approved the DXL and DXA screening. Each participant
received oral and written study information and
approved study participation by returning the question-
naire and undergoing BMD assessment.
Statistical methods
Binary data were analyzed with Fisher’s exact test, con-
tinuous normally distributed data by Student’s t-test and
asymmetric data by Mann-Whitney’s U-test. Continuous
or binary risk factors with binary outcome were also
analyzed in logistic regression models. Missing replies
for risk factor in risk models were recoded to the value
for low fracture risk, to keep high study participation
and avoid overestimation of risk ratios. Differences were
regarded as significant when two-sided p-values were <
0.05. Data were analyzed in SPSS version 13.
Results
Baseline characteristics
Participation rate was 73% (285/390) and the age span
72-98 years with nine percent living in residential care,
see Table 1. Heel BMD was assessed bilaterally for 282
women (99%) and for three women unilaterally Mean
response rate to the four clinical items in FRAMO
Index was 99%.
Around one fourth of the participants reported falls
during the last year and one third reported prior fragility
fracture (Table 1). Around one third were high risk clas-
sified by the FRAMO Index and each one of these four
risk factors was found in 19%-38% of the participants.
The total annual mortality rate was 4.2% and 24 women
(8.4%) died during 2004-2005.
Only 5% had optimal heel BMD with T-score ≥-1.0,
within the normal range of the younger reference popu-
lation (Table 1 and Figure 1). Sixty percent had T-scores
≤-2.5 SD, 41% of these 172 women had previously suf-
fered a fragility fracture.
Risk factor evaluation for hip and fragility fracture
Seven women suffered HF and 14 women any FF (alto-
gether 18 fractures; seven located at hip, four at distal
radius, four at proximal humerus and three at pubic pel-
vic bone) during the study period, yielding an annual
incidence of 1.2% and 2.5% respectively. Women who
suffered HF and FF were 4-6 years older and had
around 1.0 SD lower heel BMD, than those who did not
fracture (p < 0.01 for all comparisons).
FRAMO Index showed HF and FF prediction with OR
5.9 and 4.4 respectively (see Table 2 and Figure 2A) and
high risk classified women had an annual absolute risk
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HF sensitivity at 71% and specificity 70%. For the major-
ity of women being at low fracture risk (69%) the corre-
sponding HF and FF risk was 0.5% and 1.3% annually.
Prior fragility fracture as a single item predicted HF risk
and residential care was clearly related to increased HF
and FF risk (see Table 2).
Lowered BMD increased the HF and FF risk by OR
3.1 and 2.6 respectively for each SD T-score decrease, as
shown in Table 2. The age-adjusted BMD showed HF
a n dF Fr i s kb yO R2 . 3( 9 5 % C I :1 . 0 - 5 . 3 ,p=0 . 0 5 ) ,a n d
2.2 (95%CI: 1.2-4.2, p = 0.01) respectively, in multiple
logistic regression analyse. Higher age alone increased
the HF and FF risk by OR 2.2 and 1.8 respectively, for
every 5 years (Table 2).
For women having T-scores ≤-2.5 SD, HF and FF risk
was significantly increased only when low BMD was
combined with high FRAMO Index or a history of fragi-
lity fracture (Table 2). Isolated low BMD showed
increased HF and FF risk at a T-score level ≤-3.5 SD,
with OR 8.5 and 4.7 respectively, yielding a HF sensitiv-
ity at 71% and specificity 77%.
We identified a small high risk group by combining
high FRAMO Index, prior fragility fracture, and
T-score ≤-3.5 SD, finding 32 women suffering alto-
gether five HF with an annual absolute risk of 7.8%
and OR 23 (95%CI: 4.3-126), see Table 3. Among the
remaining 253 women of low risk two HF occured,
corresponding to a minimal HF risk at 0.4%, see Figure
2B. This risk factor combination shows a HF sensitivity
at 71% and specificity 90%.
DXL level related to DXA assessment
The 30 consequently women whose BMD was measured
with both DXL and DXA technique had a mean T-score
at heel of -2.7 SD, being lower compared to means for
hip (total hip -1.4 SD and femoral neck -2.0 SD) and to
lumbar spine (-1.3 SD, p < 0.001 for all comparisons as
paired differences). The BMD correlation was significant
between heel and hip (total hip 0.71 and femoral neck
Figure 1 Heel BMD by DXL technique on 285 women in PHC population.
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285 subjects
Hip Fractures (HF) Fragility Fractures (FF)
Risk factors 2003 N valid in risk
group (% of n)
HF in risk
group (n = 7)
OR HF (95%
CI)*
p * FF in risk
group
(n = 14)
OR FF (95%
CI)*
p*
Continuous risk factors
Heel BMD by DXL
†
T-score - Low side (SD)
† 285 (100) 7 3.1 (1.5-6.8) 0.004* 14 2.6 (1.5-4.6) 0.001*
Clinical risk factors
Age (per year) 285 (100) 7 1.2 (1.04-1.32) 0.007* 14 1.1 (1.03-1.22) 0.01*
Weight (per kg) 284 (100) 7 1.0 (0.92-1.05) 0.6 14 1.0 (0.94-1.03) 0.4
Height (per cm) 276 (97) 7 0.9 (0.82-1.03) 0.14 14 0.9 (0.84-0.99) 0.03*
Risk groups with binary items
Heel BMD by DXL
†
T-score < -1.0 SD 272 (95) 7 NA
¶ 1.0 14 NA
¶ 1.0
T-score ≤ -2.5 SD 171 (60) 6 4.1 (0.5-35) 0.2 12 4.2 (0.9-19) 0.05
T-score ≤ -3.5 SD 68 (24) 5 8.5 (1.6-45) 0.01* 8 4.7 (1.6-14) 0.006*
T-score ≤ -2.5 SD + FRAMO Index 74 (26) 5 7.6 (1.4-40) 0.01* 8 4.1 (1.49-12) 0.01*
T-score ≤ -2.5 SD + prior fragility
fracture
‡
70 (25) 5 8.2 (1.6-43) 0.01* 7 3.3 (1.1-9.8) 0.05*
T-score ≤ -3.5 SD + FRAMO Index 42 (15) 5 16.3 (3.1-87) 0.001* 7 6.7 (2.2-20) 0.001*
T-score ≤ -3.5 SD + prior fragility
fracture
‡
35 (12) 5 20.7 (3.8-111) <0.001* 6 6.3 (2.0-19) 0.003*
Main clinical risk factors as combined
FRAMO Index
§ 88 (31) 5 5.9 (1.1-31) 0.03* 9 4.4 (1.4-14) 0.01*
Main clinical risk factors as single
Age ≥ 80 years 108 (38) 5 4.4 (0.8-22) 0.11 9 3.1 (1.0-9.6) 0.05*
Weight < 60 kg 69 (24) 4 4.4 (1.0-20) 0.06 6 2.5 (0.8-7.4) 0.11
Prior fragility fracture since age 50
‡
94 (33) 5 5.2 (1.0-28) 0.04* 7 2.4 (0.8-7.5) 0.13
Impaired ability to rise five times
from chair
||
52 (19) 1 1.1 (0.1-9.9) 1.0 3 1.5 (0.4-5.6) 0.5
Other possible risk factors
Any fall last 12 months 66 (23) 1 0.5 (0.1-4.6) 0.6 5 1.9 (0.6-5.9) 0.3
Cortisone medication more than 3
months
40 (15) 3 4.7 (1.0-22) 0.07 4 2.5 (0.7-8.4) 0.13
Living in residential care (vs
community)
27 (9) 3 7.9 (1.7-38) 0.02* 5 6.3 (1.9-20) 0.006*
History of maternal hip fracture 33 (12) 0 NA
¶ 1.0 1 0.6 (0.1-4.3) 1.0
Current smoking 12 (4) 0 NA
¶ 1.0 0 NA
¶ 1.0
¶ Not analysed [NA] Odds ratio when any cellvalue at 0.
† Calcaneal BMD value measured bilaterally by DXL-tecnique. Calculations usually made on the lowest value for left and right heel.
‡ Prior fragility fracture is defined as fracture at hip, forearm, humerus, and vertebrae after 50 years of age.
§ FRAMO Index: High risk group had 2-4 risk factors of Age ≥ 80 years, weight <60 kg, prior fragility fracture and impaired ability to rise from sitting position.
Missing values for these risk factors are recoded to low fracture risk.
|| The 2 of 7 women that sustained HF and did not reply their ability to rise, were recoded to low fracture risk, as able to rise.
* p < 0.05 significant difference. Binary item test by Fisher’s Exact 2-tail. Continous item tested by logistic regression.
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tion was low and non-significant (0.26, with p = 0.17).
Scatter plot in Figure 3 illustrates BMD at heel com-
pared to hip, shows that hip osteoporosis level (-2.5 SD
at femoral neck) corresponded to a mean heel T-score
of -3.2, with 95%CI: -2.9 - -3.6 SD at that DXA level.
Applying that heel T-score threshold at -3.2 SD meant a
hip osteoporosis sensitivity of 89% and specificity of
86%. Ninety percent of these women (27/30) were
within the 95%CI limits of agreement[43].
Important risk factors for low BMD was equally dis-
tributed between these 30 DXA investigated women and
the remaining 255 DXL investigated participants, show-
ing DXL T-score at -2.72 vs -2.71 SD (p = 0.95), mean
age 80.1 vs 78.9 years (p = 0.32), mean weight 68.6 vs
68.4 kg (p = 0.94), and 33% with a history of fragility
fracture in both sub populations.
Discussion
Main findings
In this population-based study of 285 elderly women
seven HF and 14 FF occurred during a two-year period.
The practical 4-item FRAMO Index again confirmed
fracture prediction with a six-fold increased risk for HF
[35]. The high-risk classified women had an absolute HF
risk of 2.8% annually, but for the majority of women
(69%) having low risk it was only 0.5% (Figure 2A). As
expected, fractures increased at higher age with doubled
HF and FF risk for every five years age increment[44].
We found a very high absolute HF risk among the
11% (32/285) women at very low heel T-score ≤-3.5 SD
in combination with high FRAMO Index and prior
fragility fracture (Figure 2B). The remaining 89% of the
population had low HF risk.
Only 5% of this elderly population had BMD above
-1.0 SD assessed by heel DXL. The majority (60%) had
T-score ≤-2.5 SD, despite age around 79 and being heal-
thier than dropouts.
Prospectively evaluated population-based HF and FF
risk was more than doubled for every SD decrease. For
women having T-scores below the -2.5 SD threshold,
t h ef r a c t u r er i s kw a sc o n f i r m e do n l yw h e nt h e yh a d
additional clinical risk factors (Table 2)[24]. This
emphasises the importance of evaluating clinical risk
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Figure 2 Four risk factors (A) and four risk factors and heel BMD (B). (A) Hip fracture risk 2.8% annually for the 31% women having high
FRAMO Index (orange column). Remaining 69% population had risk 0.4% (green column). (B) Hip fracture risk 7.8% annually for the 11% of
population having high FRAMO Index + prior fragility fracture + BMD ≤-3.5 SD (orange column). Remaining 89% population had risk 0.4% (green
column).
Table 3 Individual absolute risk of HF and FF annually, based on FRAMO Index, prior fragility fracture and heel BMD
(T-score), alone or in combination (n = 285).
HF 2004-2005 FF 2004-2005
Risk factor combinations Women at high risk (%
of 285)
High risk
(%)
Low risk
(%)
p * High risk
(%)
Low risk
(%)
p*
FRAMO Index 88 (31) 2.8 0.5 0.03 * 5.1 1.3 0.01 *
Heel BMD ≤ -2.5 SD 171 (60) 1.8 0.4 0.2 3.5 0.9 0.05
Heel BMD ≤ -3.5 SD + prior fragility fracture +
FRAMO Index
32 (11) 7.8 0.4 <0.001* 9.4 1.6 0.002*
* Exact P-value as Fisher’s two-sided test for binary variables, p < 0.05 as a significant difference.
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gical treatment[25,29,45].
Hip osteoporosis level corresponded, in a representa-
tive DXA assessed subgroup, to a lower heel BMD
around -3.2 SD, indicating a threshold within the 95%CI
-2.9 to -3.6 SD (Figure 3).
Other studies
Our now revalidated clinical 4-item FRAMO Index
2004-2005 showed a HF risk of 5.9 and a FF risk of 4.4.
These risks are similar to those of the previous study
period 2002-2003 (HF and FF risk at 7.5 and 6.7 respec-
tively)[35]. The positive predictive two-year FRAMO
Index value for HF was now 5.1%, equivalent with our
previous study (5.4%)[35] and another extended 6-item
model (5.6%)[29].
The DXL measured prevalence of “heel osteoporosis”
(≤-2.5) was as high as 60% in this Swedish women
population, average age 79 years. Hip osteoporosis pre-
valence in white US women at similar ages was 24.5-
47.5% measured with the DXA reference method[34].
Among the 30 consecutive chosen women in our
study being DXA assessed, we found osteoporosis
among 30% (9 of 30, see Figure 3), finding the same
prevalence as in a previous DXA assessment study[34],
see further comments below[46].
Age-adjusted HF and FF risk showed an OR of 2.2-2.3
per SD decrease, with our mobile DXL technique, equal
in HF prediction as compared to older heel BMD
assessment X-ray techniques (RR = 2.0)[31]. With sta-
tionary hip assessed DXA the HF prediction showed RR
at 2.6 (relative risk) per SD decrease[31], a method
being evaluated for both fracture prediction and phar-
macological prevention. In our study the extended bone
strengthening therapy at low BMD possibly prevented
some fractures, which would lower actual fracture ratios.
Mean heel DXL T-scores were significantly lower
compared to DXA (-1.3 vs total hip and -0.7 to femoral
neck) for a representative subgroup in our study. These
results were close to findings in another study (-1.1 and
-0.5 SD respectively)[46], to take into account when
defining osteoporosis using DXL assessed BMD at the
Figure 3 T-score correlation for heel BMD compared to hip on 30 women. The linear regression line crosses hip osteoporosis level -2.5 SD
at the mean heel T-score of -3.2 SD, with the 95%CI of means -2.9 to -3.6 SD. Only one woman with high heel T-score >-3.2 SD had hip
osteoporosis. Three women with low heel T-score ≤-3.2 SD did not have hip osteoporosis.
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T-score threshold intervals, either for treatment or for
further DXA assessment[47].
Still, fracture preventive treatment should be based on
t h ea b s o l u t ef r a c t u r er i s k ,mainly dependent on clinical
risk factors, such as age, gender, prior fragility fracture,
heredity, cortisone medication, etc[20,24-27,33]. For
clinical risk groups BMD assessment is valuable
[19,20,24,28,29] before specific bone enhancing therapy.
Limitations
Our study was small with few fractures occurring during
the two-year observation period. This gives a wide 95%CI
for the binary variables especially, contributing to large
OR variations for the single risk items as well. On the
other hand, items causing significant results usually
showed high OR, identifying potential strong risk factors.
We combined several risk factors into our risk model,
which stabilizes and reduces the influence of random var-
iation. Despite few fracture outcomes our main findings
on risk estimates were close to other study results, evalu-
ating HF prediction with FRAMO Index and heel BMD
with DXL method [31,36]. The combination of these four
clinical risk factors and very low heel BMD showed very
high OR and was strongly significant (p < 0.001), 95%CI
being wide but the lower limit still above four. Enhanced
HF prediction by applying BMD on clinical risk groups is
found in other studies[24,28], although the more precise
OR of our risk factor combination with BMD has not
been determined before.
The population in this study was involved in a fracture
prevention programme in 2003. Lower fall tendency and
improved up-rise ability were reported during 2004[39]
which to some extent lowered these risk model items
and maybe also the fracture prediction of the risk model
itself.
Two of the seven women who acquired HF during the
observation period did not report their ability to rise in
the 2003 survey, while in 2001 they reported impaired
ability to rise. Had they reported the same ability in
2003 as in 2001, this would have adjusted the risk esti-
mate for HF upwards.
Further studies
Fracture prediction using the FRAMO Index alone and
in combination with portable BMD DXL assessment
ought to be repeated in larger urban populations[36],
also of non-Scandinavian origin both for men and
women to delimit the optimal thresholds for fracture
prediction.
Implications
In this pilot study we reassessed the practical clinical
FRAMO Index and confirmed its fracture predictive
ability[35]. This supports the use of clinical risk factors
a sas i m p l es c r e e n i n gt o o li naP H Cp o p u l a t i o n [ 3 6 ] .
Moreover, it identifies the majority of elderly women at
low HF risk, thus with minor need for specific fracture
prevention[35].
A high FRAMO Index together with a low heel BMD
(T-score ≤-3.5 SD), and a previous fragility fracture
identified a subgroup of women with a very high risk of
fracture. This selection optimized fracture prediction.
Clinical risk factors and mobile heel BMD assessment
combined seems to delimit women at marked fracture
risk, and identifies a large majority of women being at
minimal risk, especially for HF (Table 3). This seems
f e a s i b l es i n c eap o r t a b l eD X Linstrument was practical
to use for bilateral heel BMD screening in PHC. If these
results are confirmed in larger studies this screening
procedure could concentrate HF prevention to persons
at very high risk. This would lower prevention treatment
costs and side-effects of unnecessary prevention.
Conclusions
In this population-based pilot study of 285 elderly
women we re-identified high risk groups for hip fracture
(HF) and fragility fracture (FF) by prospectively using
the practical clinical 4-item FRAMO Index, with results
similar to our previous study. We found that the HF
and FF risk increased when heel BMD in calcaneal bone
was low. We used the mobile heel DXL technique that
predicted HF with the same accuracy as older heel
BMD X-ray techniques. We thus identified a small
group of women (11%) that sustained most HF (5 of 7)
by using a combination of a high FRAMO Index, prior
fragility fracture, and heel determined BMD below -3.5
SD. Our plain clinical 4-item screening method for hip
fracture could improve HF prevention, by directing
more resources to the women at actual high risk. Com-
bining the 4-item screening method with heel BMD
assessment seemed to improve the fracture prediction,
although this needs to be tried in larger urban
populations.
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